Business Context and Reporting Period
This Form 8-K Current Report was filed by Keros Therapeutics, Inc. on October 15, 2024, regarding events occurring on October 16, 2024. The filing discloses the appointment of a new Chief Medical Officer and the terms of the associated employment agreement.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and employment terms.
- Base Salary: $510,000 annually.
- Target Bonus: 40% of annual base salary.
- Equity Grant: Stock option to purchase up to 110,000 shares of common stock.
- Exercise Price: Equal to the closing price on the grant date.
Material Changes
The primary material change is the leadership transition in the medical division:
- Appointment: Yung H. Chyung, M.D., appointed as Chief Medical Officer, effective November 1, 2024.
- Departure: Simon Cooper, M.B.B.S, is succeeded in the role of Chief Medical Officer.
- Background: Dr. Chyung previously served as Executive Vice President and Chief Medical Officer at Tourmaline Bio, Inc. (2022–2024) and Chief Medical Officer at Scholar Rock Holding Corporation (2016–2022).
Outlook, Risks, and Unusual Items
The filing details specific severance and change of control provisions within the employment agreement:
- Standard Severance: Involuntary termination without cause (outside of a change of control) or resignation for good reason entitles Dr. Chyung to nine months of base salary and COBRA premiums.
- Change of Control Severance: If termination occurs within 12 months of a change of control, benefits include 12 months of base salary, acceleration of all unvested equity awards, a lump sum equal to 100% of the target bonus, and 12 months of COBRA premiums.
- Restrictions: The agreement includes a 12-month non-competition and non-solicitation covenant following termination.
- Indemnification: The Company will enter into a standard indemnification agreement covering expenses, damages, and legal fees incurred in the capacity of an executive officer.
Investor Verification Checklist
- Verify the exact grant date and exercise price for the 110,000 stock options once finalized.
- Review the full text of the Employment Agreement (Exhibit 10.1) for specific definitions of "Cause," "Good Reason," and "Change of Control."
- Confirm the vesting commencement date to calculate the precise schedule for the 25% initial vesting and subsequent quarterly vesting.
- Assess the impact of the leadership change on the Company's clinical development pipeline and strategic direction.